Vaxcyte (PCVX) Receivables (2021 - 2024)

Vaxcyte (PCVX) has 4 years of Receivables data on file, last reported at $17.9 million in Q3 2024.

• On a quarterly basis, Receivables rose 235.69% year-over-year to $17.9 million in Q3 2024; TTM through Sep 2024 was $17.9 million, a 235.69% increase from a year earlier, with the FY2023 full-year figure at $3.6 million, down 6.96% from the prior year.
• Receivables for Q3 2024 stood at $17.9 million, up from $8.5 million in the prior quarter.
• Over the last five years, Receivables for PCVX reached as high as $17.9 million in Q3 2024 and fell as low as $3.6 million in Q4 2023.
• Historically, Receivables has averaged $7.5 million across 4 years, with a median of $5.3 million in 2023.
• Across the five-year window, Receivables retreated 6.96% in 2023 and jumped 235.69% in 2024, its largest moves.
• Year by year, Receivables stood at $5.0 million in 2021, then retreated by 22.46% to $3.9 million in 2022, then declined by 6.96% to $3.6 million in 2023, then surged by 395.48% to $17.9 million in 2024.
• Per Business Quant data, the three most recent Receivables figures were $17.9 million in Q3 2024, $8.5 million in Q2 2024, and $8.1 million in Q1 2024.